Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06272864 · ClinicalTrials.gov registry record
BostonGene and Exigent Genomic INsight Study
A clinical trial of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by BostonGene.
- Recruiting
- Registry status
- 400
- Enrollment target
- 7
- Study locations
NCT06272864: Recruiting study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by BostonGene.
NCT06272864 is a study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by BostonGene. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06272864, a study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by BostonGene.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 7
- Study locations
Study Summary
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
Primary Outcome
the frequency of actionable findings identified by a comprehensive (WES/RNA) sequencing platform (BostonGene Tumor Portrait) in advanced cancer patients. Actionable findings will include: genomic findings such as fusions, single nucleotide variants (SNVs), insertion/deletion alterations (indels), copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), frameshifts, rearrangements, gene expression levels, genome instability and loss of heterozygosity, cell
Conditions Studied
Study Locations (7)
Arkansas
- Highlands Oncology Group - Rogers
California
- Stockton Hematology Oncology Medical Group - Stockton
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
New Mexico
- New Mexico Cancer Center - Albuquerque
Oklahoma
- Oklahoma Cancer Specialists and Research Institute - Tulsa
Texas
- Oncology Consultants - Houston
Washington
- Northwest Medical Specialities - Puyallup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2028-01-08 |
What NCT06272864 shows while recruiting
NCT06272864 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06272864 lists 7 locations in 7 states (Arkansas, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT06272864 about?
NCT06272864 is a clinical study titled "BostonGene and Exigent Genomic INsight Study". The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical ...
What is the current status of trial NCT06272864?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-04-08. Estimated completion is 2028-01-08.
What conditions does trial NCT06272864 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Sarcoma.
Who is sponsoring clinical trial NCT06272864?
This trial is sponsored by BostonGene, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06272864 being conducted?
This trial has 7 study locations across Arkansas, California, Indiana, New Mexico, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06272864's enrollment target sits among peer trials
400 233rd of 1224 higher than 981 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02285582 · 400 participants
International Rare Histiocytic Disorders Registry (IRHDR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI